451 results about "TG - Triglyceride" patented technology

A synergistic composition for improving the bioaccessibility of minerals comprises lutein, a casein phosphopeptide, or a 1, 3-dioleoyl-2-palmitic acid triglyceride, preferably in combination with one or more non-digestible oligosaccharides. These compositions are useful for the prevention and / or treatment of mineral deficiency and related conditions, preferably anemia, said minerals comprising iron and / or calcium.

Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and / or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker combination and application thereof in IDH-1 gene mutation detection. The biomarker combination comprises one or more of the following lipid metabolites: a third component of high-density lipoprotein-triglyceride, a fourth component of high-density lipoprotein-triglyceride, high-density lipoprotein-triglyceride, lactic acid and sphingomyelin. Whether a glioblastoma patient carries IDH-1 gene mutation or not is judged through a plurality of biomarkers, the method has the advantages of being good in sensitivity and specificity, small in patient trauma, capable of overcoming individual differences and suitable for large-scale screening, and a new solution is provided for clinical patient diagnosis.

The invention discloses a method for analyzing a fine structure of oxidized triglyceride based on mass spectrum data, which comprises the following steps: integrating CID and EAD complementary mass spectrum data, collecting four spectrograms of CID MS2 ([M + Na] < + >), CID MS2 ([M + NH4] < + >), EAD MS2 ([M + Na] < + >) and EAD MS2 ([M + NH4] < + >) of components, strictly arranging the spectrograms according to the sequence, designing a new prediction-hit strategy, and gradually deducing, analyzing and verifying the structure. The strategy successfully identifies fine structures of oxidized triglycerides such as hydroxyl, ketone group, epoxy group and peroxy group, and more completely describes information such as types, quantity and positions of oxidized groups, positions of unsaturated double bonds, sn distribution of fatty acid and the like. By performing cross validation on the information of each region in the four spectrograms of each substance, the method remarkably improves the identification accuracy.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

The invention discloses a horse milk-derived small molecule peptide, the amino acid sequence of which is Met-Ser-Pro-Phe (MSPF), and the molecular weight of which is 480.571 Da. The small molecule peptide disclosed by the invention has the activity of inhibiting pancreatic lipase (PL), the inhibition rate on the pancreatic lipase is 61.44%, and the accumulation of the content of triglyceride (TG) in oleic acid-induced human liver cancer (HepG2) cells can be reduced, so that the small molecule peptide can be used for inhibiting the pancreatic lipase (PL). The small molecule peptide can be applied to preparation of preparations for treating or assisting in treating hyperlipidemia and obese people, is simple to prepare, and is suitable for industrial production and market popularization and application.

The invention relates to the technical field of genetic engineering, in particular to a recombinant vector, an expression plasmid, a recombinant schizochytrium limacinum mutant and a method for increasing the DHA content of microorganisms. The LIP1 gene for coding lipase in the microbial lipid droplet protein is knocked out through a homologous recombination technology, and the production of lipase in the microbial lipid droplet can be effectively inhibited, so that the hydrolysis process of triglyceride of polyunsaturated fatty acid stored in the lipid droplet to glycerol and free fatty acid in the later stage of microbial culture is blocked, and DHA is prevented from being lost from a TAG repository; experimental verification shows that in microorganisms represented by schizochytrium limacinum, the DHA content can be increased by 21.8% compared with that of a wild type, the yield and purity of DHA are increased, the stability of the microbial fermentation process is guaranteed, and application and popularization are facilitated.

The present invention relates to an enzyme catalyst for preparing a dicarboxylic acid and a method for preparing a dicarboxylic acid using the same. The enzyme catalyst is prepared by a method comprising the following steps: (1) carrying out fermentation culture on enzyme-producing microorganisms in a culture medium to obtain a crude enzyme solution, and (2) immobilizing the crude enzyme solution on a molecular sieve to obtain the enzyme catalyst, wherein the enzyme producing microorganisms are selected from candida tropicalis, candida sake, pichia pastoris, saccharomyces cerevisiae, lactobacillus brevis, corynebacterium glutamicum, bacillus subtilis, bacillus cereus, escherichia coli and pseudomonas aeruginosa. The method comprises the following steps: in a PBS buffer solution, mixing triglyceride with the enzyme catalyst, and carrying out catalytic reaction under stirring at 20-50 DEG C; and then carrying out hydrolysis reaction at the temperature of 250-300 DEG C under the pressure of 30-100 bar. According to the method, the enzyme catalyst and the molecular sieve are immobilized, so that other oxidants or catalysts are not required to be added while the dicarboxylic acid with higher yield is obtained.

The invention relates to a diacylglycerol acyltransferase capable of synthesizing triglyceride as well as a coding gene and application of the diacylglycerol acyltransferase, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the diacylglycerol acyltransferase is as shown in SEQ ID NO.1, and the amino acid sequence of the diacylglycerol acyltransferase is as shown in SEQ ID NO.2. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

The invention discloses an immobilized enzyme reactor for preparing low-carbon-chain triglyceride, and relates to the technical field of bioreactors, the immobilized enzyme reactor comprises a reactor body, a bearing ball carrying enzyme, a feeding pipe, a discharging pipe, a conveying channel, a conveying mechanism and a collector; a filter pipe is arranged in the reactor body, the upper end of the filter pipe is communicated with the conveying channel through a feeding pipe, the lower end of the filter pipe is communicated with a collector through a discharging pipe, and the lower end of the collector is communicated with the conveying channel; unused bearing balls are contained in the collector, when the immobilized enzyme needs to be recycled, the vibrator on the filter pipe vibrates the filter pipe, the bearing balls in the filter pipe roll into the collector from the discharging pipe under the combined action of vibration and gravity, and the unused bearing balls in the collector are moved to the feeding pipe through the conveying mechanism and finally enter the filter pipe; an operator can open the cover plate of the collector and take out the used bearing balls from the discharge port, so that the effect of recycling the immobilized enzyme is realized.

The invention discloses a lipase A mutant as well as a preparation method and application thereof, and belongs to the technical field of biology. The lipase A mutant is a protein obtained by carrying out one or more amino acid residue changes on at least one of the following sites of an amino acid sequence as shown in SEQ ID NO: 1: the 94th site, the 117th site, the 121st site, the 122nd site, the 283rd site and the 431st site; wherein the change is selected from at least one of substitution, deletion and addition. Through rational design, lipase A from Candida antarctica is subjected to site-directed mutagenesis, the Candida antarctica lipase A mutant with catalytic activity and selectivity to the sn-2 site of triglyceride remarkably improved is obtained, and when 1, 3-diglyceride is prepared, the Candida antarctica lipase A mutant can remarkably improve the yield of 1, 3-diglyceride. The yield of the 1, 3-diglyceride is improved.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention provides a triglyceride determination kit, the kit comprises a reagent 1 and a reagent 2, the reagent 1 comprises the following main components: piperazine-1, 4-diethyl sulfonic acid (PIPES) buffer solution (pH 6.8), glycerophosphate oxidase (GPO), peroxidase (POD), triadenosine phosphate (ATP), chromogen, a surfactant, a stabilizer and a preservative; and the reagent 2 comprises the following main components: a piperazine-1, 4-diethyl sulfonic acid (PIPES) buffer solution (pH is 6.5), lipoprotein esterase (LPL), glycerol kinase (GK), 4-aminoantipyrine (4-AA), a surfactant, a stabilizer and a preservative. By optimizing a chromogen substrate in the reagent and adding potassium ferrocyanide, the linear range of the prepared kit is wider, and the bottle opening test is more stable.

The invention discloses a polypeptide-coated anti-wrinkle composition containing a red camellia extract and application. The polypeptide-coated anti-wrinkle composition comprises a component A, a component B and a component C, wherein the component A is prepared from palmitoyl tripeptide-5, palmitoyl tetrapeptide-7, polyhydric alcohol A and caprylic / capric triglyceride; the component B is prepared from PPG-13-decyl tetradecyl alcohol polyether-24 and polyhydric alcohol B; and the component C comprises water and a camellia japonica extract. According to the invention, the dissolvability problem of palmitoyl peptide is firstly solved, and then palmitoyl peptide is wrapped by a low-energy emulsification technology, so that the compatibility problem of the camellia japonica extract and palmitoyl peptide is solved, and a flowing liquid with a transparent appearance is obtained, is more stable and safer, has better effects, is convenient to apply, can promote the generation of collagen, and has a good application prospect. The activity of elastinase is inhibited, and the effects of improving wrinkles and delaying senescence are better achieved.

The invention discloses application of an overexpressed carp lpla gene in regulation and control of expression of cyprinid fish tissue-related genes, and relates to the field of gene engineering, in particular to application of the overexpressed carp lpla gene in regulation and control of cyprinid fish tissue-related genes. The overexpressed carp lpla gene is applied to regulation and control of contents of lipid indexes of total cholesterol TC and triglyceride TG of different tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulation and control of fat marker genes lpla, ppar gamma, Fabp3, fast and acaca of livers and muscle tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulating and controlling the relative expression quantity of carp liver cell fat metabolism related genes lpla, ppar gamma, Fabp3, fast, acaca, hsl and pnpla2. The overexpressed carp lpla gene can regulate and control lipid deposition in different tissues in zebra fish, and a research model is provided for lpla to regulate and control fat deposition and differentiation. According to the overexpressed carp lpla gene disclosed by the invention, lpla high-expression carp hepatocytes are obtained through a liposome transfection technology, so that fat key gene expression in the carp hepatocytes is changed.

The invention discloses a model for predicting the progression hepatic fibrosis risk of a WD long-term maintenance treatment patient and a design method thereof, and relates to the technical field of medical information, the prediction model comprises the following steps: an input module receives patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER), and the input module receives the patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER); the processing module obtains single scores corresponding to the seven independent risk factors, the single scores are added to obtain a total score, the prediction probability corresponding to the total score is the risk of the progression-stage hepatic fibrosis of the WD long-term maintenance treatment patient, and the prediction risk probability is output through the output module. The column diagram prediction model established by the invention has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of progression-stage hepatic fibrosis of WD long-term maintenance treatment patients.

The invention relates to a venturi effect preparation method of a terbinafine film-forming composition, which comprises the following steps: 1) dissolving terbinafine or terbinafine hydrochloride in a solvent to obtain a medicine liquid; 2) mixing the medium chain triglyceride and the medicine liquid to obtain mixed liquid; 3) performing dry mixing with a film-forming agent to obtain a dry-mixed polymer; and 4) adding the dry-mixed polymer into the mixed liquid through a Venturi effect, and hydrating the obtained polymer. The preparation method has the advantages that the composition proportion, the preparation method and the mixing equipment are reasonable in design, the dry-mixed polymer is introduced into the liquid by utilizing the Venturi effect, lumps can be effectively crushed, the hydration effect is improved, the preparation method is efficient and economical, and the preparation time can be effectively saved and the energy consumption can be effectively reduced on the premise of ensuring the use effect.

The invention provides a method for preparing alpha-olefin from a triglyceride compound, and relates to the technical field of organic synthesis. According to the method provided by the invention, in a solvent environment, a hydrogen-containing atmosphere and at 50-300 DEG C, a triglyceride compound I reacts under the catalysis of a NiCu bimetallic catalyst to generate alpha-olefin II-1, alpha-olefin II-2 and alpha-olefin II-3. According to the method provided by the invention, the triglyceride compound is adopted as a reaction substrate, the alpha-olefin compound can be efficiently synthesized, the reaction is green and efficient, the atom utilization rate is high, and no pollution is caused.

The invention discloses a composition containing achillea millefolium extract, which is prepared from the following ingredients in percentage by weight: 45 to 55 percent of glycerol, 4 to 6 percent of hydrogenated lecithin, 3 to 5 percent of caprylic / capric triglyceride, 1 to 3 percent of 1, 2-hexanediol, 0.8 to 1.2 percent of achillea millefolium extract, 0.4 to 0.6 percent of ergothioneine and the balance of water. Through precise compounding of the achillea millefolium extract and the ergothioneine, the dual effects of anti-inflammation and skin repair are achieved, flavonoid and organic acid components in the achillea millefolium extract can effectively inhibit release of inflammatory mediators such as IL-6 and TNF-alpha, and sensitive symptoms such as red and swollen and pruritus are relieved.

The invention relates to a postoperative hypoxemia risk prediction method and system.The postoperative hypoxemia risk prediction method comprises the steps that patient data are obtained, and the patient data comprise the body mass index, the platelet count, the fibrinogen level and the triglyceride-glucose index; the patient data are input into a pre-trained postoperative hypoxemia risk prediction model to obtain a postoperative hypoxemia risk prediction result, and the postoperative hypoxemia risk prediction result comprises the postoperative hypoxemia occurrence probability, the 95% confidence interval and the model parameters. The method has the advantages that the preoperative data, namely BMI, PLT, FIB and TyG, can be used for predicting the postoperative hypoxemia risk of the patient, so that the patient with high postoperative hypoxemia risk can be focused after the operation; preoperative data is easy to obtain and can be obtained from routine examination of a patient, and the method is simple, rapid and convenient to operate; the speed of obtaining the postoperative hypoxemia risk prediction result is high, and the accuracy rate is high.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention relates to a pharmaceutical composition for treating hyperlipidemia. The invention relates to the field of medicines, in particular to a pharmaceutical composition of probucol and statins, a pharmaceutical composition or a medicine box containing probucol and statins, and application of the pharmaceutical composition, the pharmaceutical composition or the medicine box in preparation of medicines for treating hyperlipidemia, in particular severe hypertriglyceridemia and severe hypercholesteremia, and application of the pharmaceutical composition, the pharmaceutical composition or the medicine box in preparation of medicines for treating hyperlipidemia, in particular severe hypertriglyceridemia and severe hypercholesteremia. The pharmaceutical composition, the pharmaceutical composition containing the probucol and the statins or the medicine box is characterized in that the pharmaceutical composition, the pharmaceutical composition containing the probucol and the statins or the medicine box containing the probucol and the statins contains a small dose of the probucol and the statins, and the probucol and the statins are configured to be in a form of simultaneous administration.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention provides a liquid crystal bionic water-locking and oxygen-permeating nursing composition as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The skin care product is prepared from components in percentage by weight as follows: 20%-40% of glycerin, 5%-10% of hydrogenated lecithin, 5%-10% of phytosterols, 0.1%-0.5% of sodium stearoyl glutamate, 0.01%-0.05% of sodium methyl stearoyl taurate, 0.1%-1% of ceramide NP, 1%-10% of caprylic / capric triglyceride, 1%-10% of squalane, 0.1%-1% of tocopheryl acetate, 0.01%-0.3% of DNA sodium, 0.001%-0.1% of fibronectin and the balance of water. 0.001-0.1% of soluble collagen and the balance of water. The liquid crystal bionic water-locking and oxygen-permeating nursing composition provided by the invention can better form a breathable protective film on the surface of skin, reduce water loss of the skin and help to repair a damaged skin barrier, so that the water-locking and oxygen-permeating nursing effect is achieved.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to the field of medium-long-chain triglyceride, and particularly discloses medium-long-carbon-chain triglyceride edible oil and a preparation method thereof. The preparation method of the medium-long carbon chain triglyceride edible oil comprises the following steps: carrying out reaction activation on sialic acid and an oxidizing agent to obtain an activated sialic acid derivative, adding the activated sialic acid derivative and lipase into a phosphate buffer solution, carrying out stirring reaction at 4 DEG C for 12-24 hours, then adding sorbitan monooleate, carrying out stirring reaction at 30-40 DEG C for 20-40 minutes, and carrying out centrifugation to obtain the medium-long carbon chain triglyceride edible oil. Freezing and drying to obtain the functionalized lipase; and adding purple perilla seed oil, medium-chain triglyceride and the functionalized lipase into a reaction kettle for reaction, removing free fatty acid in a crude product by using a molecular distillation technology, and extracting and purifying by using ethanol to obtain the medium-chain and long-chain triglyceride edible oil. The medium-long carbon chain triglyceride edible oil has the advantages of being high in yield, rich in alpha-linolenic acid and high in nutritive value.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The invention relates to an exhaled air condensate metabolite composition, a kit and a method for predicting invasive lung adenocarcinoma. The expired gas condensate metabolite composition for predicting the invasive lung adenocarcinoma comprises lysyl-valine, lysophosphatidyl glycerol (19: 0), vanillyl-glucose, hydroxyproline-threonine, phenylalanine, dihydroxy benzophenone, palmitoyl glycine, triglyceride (43: 0), monobutyl phthalate, hydroxyphenyl propionic acid, oleoyl glycine and dodecanedioic acid. The preparation method comprises the following steps: adding 4-chlorophenylalanine and The kit for predicting the invasive lung adenocarcinoma comprises an internal standard substance required for detecting the metabolite combination. The combined marker provided by the invention has the characteristics of high sensitivity and high specificity on the diagnosis of the invasive lung adenocarcinoma.

A use of a nutritional composition in promoting the bidirectional development of the gut and brain via the gut-brain axis. The nutritional composition comprises the following essential components: docosahexaenoic acid, eicosatetraenoic acid, galactooligosaccharide, 1,3-dioleic acid-2-palmitic acid triglyceride, lutein, nucleotide, lactoferrin, casein phosphopeptide, and probiotics. By combining and strengthening multiple functional active components, the gut health and brain cognitive development of the organism can be bidirectionally promoted by means of the microbiota-gut-brain axis. In particular, the present application can promote the regulation of flora in the gut of the organism, increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria related to brain development diseases. The content of butyric acid in the gut can be increased, and the contents of acetic acid and propionic acid are decreased to promote brain and cognitive development.

The invention relates to a molecular target capable of specifically reducing cholesterol level without interfering triglyceride metabolism and application of the molecular target. The molecular target is the C terminal of ANGPTL3 protein. The invention also relates to an application of the inhibitor of the C terminal of the targeted ANGPLT3 protein (Angiopoietin-like3, angiopoietin-like protein 3) in preparation of a medicine, and the medicine is used for treating hypercholesteremia, atherosclerosis and coronary heart disease, and also relates to an application of the inhibitor of the C terminal of the targeted ANGPLT3 protein (Angiopoietin-like protein 3) in preparation of the medicine.